Strategic Licensing Oleolive operates under an exclusive license to produce high-quality oleocanthal, presenting a near-term sales opportunity to supply researchers and biotech firms focused on oxidative stress, neurodegenerative diseases and cancer research.

Academic Partnerships With recognition from a university-backed license and a track record of grant-winning research awards, there is potential to collaborate on funded research programs, contract development, and co-branded studies to drive orders for oleocanthal extracts and related formulations.

Niche Supplements Oleolive has already commercialized an oleocanthal-rich supplement Oligen and has CBD related product launches, indicating a path to cross-sell to nutraceutical retailers, clinics, and direct-to-consumer channels seeking olive oil–based health claims.

Targeted Markets Current emphasis on health benefits and Alzheimer’s research points to opportunities in biotech research labs, contract research organizations, and academic groups pursuing inflammatory and neurodegenerative endpoints.

Financial Footing With a modest revenue range and early-stage funding, Oleolive may be open to pilot collaborations, revenue-sharing pilot programs, or milestone-based partnerships to scale both research-grade and consumer products while de-risking initial deals.